This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SONN Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Sonnet BioTherapeutics Stock (NASDAQ:SONN) Get Sonnet BioTherapeutics alerts:Sign Up Key Stats Today's Range$1.26▼$3.2350-Day Range$1.02▼$5.9252-Week Range$1.08▼$19.30Volume10.08 million shsAverage Volume2.09 million shsMarket Capitalization$7.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing innovative cytokine-based therapeutics for oncology and autoimmune disorders. The company’s platform centers on engineering human cytokines, notably interleukin-2 and related molecules, fused to carrier proteins such as human serum albumin. This design aims to extend circulating half-life, enhance tumor localization, and minimize systemic toxicity compared with traditional cytokine therapies. Sonnet’s lead pipeline candidates are in early-phase clinical trials for the treatment of solid tumors, where the company seeks to demonstrate improved efficacy and safety. In parallel, Sonnet is advancing preclinical immunocytokine programs targeting specific aspects of the tumor microenvironment to further leverage its fusion protein technology across multiple cancer indications. Headquartered in San Diego, California, Sonnet BioTherapeutics conducts research and development operations in the United States. The management team comprises seasoned industry professionals with expertise in immuno-oncology, biologics development, and clinical strategy, positioning the company to progress its pipeline toward later-stage trials and potential partnerships.AI Generated. May Contain Errors. Read More Receive SONN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SONN Stock News HeadlinesHyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business CombinationDecember 2, 2025 | globenewswire.comSonnet BioTherapeutics stockholders approve Hyperliquid Strategies combinationDecember 2, 2025 | msn.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.July 31 at 1:00 AM | Chaikin Analytics (Ad)Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies IncDecember 2, 2025 | finance.yahoo.comSonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special MeetingNovember 18, 2025 | globenewswire.comSonnet BioTherapeutics Announces Special Meeting for Business Combination VoteOctober 29, 2025 | msn.comHyperliquid’s HYPE soars as Wall Street backs $888 million mergerOctober 23, 2025 | msn.comHyperliquid Wants $1B to Power Its Next HYPE Token ExpansionOctober 23, 2025 | finance.yahoo.comSee More Headlines SONN Stock Analysis - Frequently Asked Questions How were Sonnet BioTherapeutics' earnings last quarter? Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.46. When did Sonnet BioTherapeutics' stock split? Sonnet BioTherapeutics shares reverse split on Sunday, September 29th 2024.The 1-8 reverse split was announced on Sunday, September 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Sunday, September 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Sonnet BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sonnet BioTherapeutics investors own include Plug Power (PLUG), SNDL (SNDL), NIO (NIO), Zomedica (ZOM), VYNE Therapeutics (VYNE), Avino Silver & Gold Mines (ASM) and Dare Bioscience (DARE). Company Calendar Last Earnings8/13/2025Today7/31/2026Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SONN CIK1106838 Webwww.chanticleerholdings.com Phone609-375-2227Fax704-366-2463Employees10Year Founded2011Profitability EPS (Trailing Twelve Months)($8.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.44 million Net MarginsN/A Pretax Margin-1,339.60% Return on Equity-4,646.10% Return on Assets-342.21% Debt Debt-to-Equity RatioN/A Current Ratio0.26 Quick Ratio0.26 Sales & Book Value Annual Sales$1 million Price / Sales7.18 Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-1.43Miscellaneous Outstanding Shares7,078,000Free Float6,478,000Market Cap$7.18 million OptionableNot Optionable Beta1.48 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SONN) was last updated on 7/31/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SONN Stock Alerts